Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder
NCT ID: NCT01090713
Last Updated: 2016-07-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
50 participants
INTERVENTIONAL
2010-01-31
2012-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects
NCT02659488
Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder
NCT01291173
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
NCT02009163
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment
NCT03926052
Open Label Extension in Adults With Binge Eating Disorder (BED)
NCT01657019
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lisdexamfetamine
drug
lisdexamfetamine
oral; 20-70mg/day
Placebo
Placebo comparator
Placebo control
20-70mg; oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lisdexamfetamine
oral; 20-70mg/day
Placebo control
20-70mg; oral
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subjects who are displaying clinically significant suicidality or homicidality.
* A current or recent (within 6 months of the start of study medication) DSM-IV diagnosis of substance abuse or dependence
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shire
INDUSTRY
University of Cincinnati
OTHER
Lindner Center of HOPE
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lindner Center of HOPE
Mason, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LDX in BED
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.